CTOs on the Move

Aduro Biotech

www.aduro.com

 
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.aduro.com
  • 626 Bancroft Way #3C
    Berkeley, CA USA 94710
  • Phone: 510.848.4400

Executives

Name Title Contact Details

Similar Companies

EMD Biosciences

EMD Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arnold A Welu Dental Laboratory

Arnold A Welu Dental Laboratory, Inc is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seed Health

Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions.

Casebia

Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.

Terumo Blood and Cell Technologies

Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries. As the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction, we believe in the potential of blood to do even more for patients than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers. Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to our vision of working together for better lives and our promise to unlock the potential of blood and cells. One way we back these words is through our pledge to be a conscientious corporate citizen and conduct our business in a way that provides social, environmental and economic benefit. At Terumo Blood and Cell Technologies, discovery never stops. We share a passion for thinking in new and different ways and we are proud to support education and research through a variety of community involvement activities as well as by providing grants to advance treatment options for patients. We know the work we do matters and has the potential to fundamentally improve health care. We remain dedicated to ensuring the lifesaving gift of blood is available around the world and to meeting and exceeding the needs of our customers and the patients we ultimately serve.